Velcade and Gastrointestinal hypomotility - a phase IV clinical study of FDA data

Summary:

Gastrointestinal hypomotility is reported as a side effect among people who take Velcade (bortezomib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Prednisone, and have Waldenstrom's macroglobulinaemia.

The phase IV clinical study analyzes which people have Gastrointestinal hypomotility when taking Velcade. It is created by eHealthMe based on reports of 66,250 people who have side effects when taking Velcade from the FDA, and is updated regularly.

What is Velcade?

Velcade has active ingredients of bortezomib. It is often used in multiple myeloma. eHealthMe is studying from 66,422 Velcade users. Check the latest studies of Velcade.

What is Gastrointestinal hypomotility?

Gastrointestinal hypomotility (less activity of the intestinal tract) is found to be associated with 205 drugs and 437 conditions by eHealthMe. Check the latest studies of Gastrointestinal hypomotility.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

66,250 people reported to have side effects when taking Velcade.
Among them, 28 people (0.04%) have Gastrointestinal hypomotility.

Could Velcade cause Gastrointestinal hypomotility?

Among these 28 people:

How long have people been on Velcade when they have Gastrointestinal hypomotility? *

What is the gender of people who have Gastrointestinal hypomotility when taking Velcade? *

female: 50 %
male: 50 %

What is the age of people who have Gastrointestinal hypomotility when taking Velcade? *

What are other drugs people take besides Velcade? *

What are other side effects people have besides Gastrointestinal hypomotility? *

Constipation: 8 people, 28.57%
Abdominal Distension: 6 people, 21.43%
Respiratory Tract Infection: 6 people, 21.43%
Diarrhea: 5 people, 17.86%
Urinary Tract Infection: 4 people, 14.29%
Flatulence (flatus expelled through the anus): 4 people, 14.29%
Blood Glucose Increased: 3 people, 10.71%
Escherichia Infection (bacterial infection by escherichia coli): 3 people, 10.71%
Interstitial Lung Disease: 3 people, 10.71%
Hyporeflexia (a condition of below normal or absent reflexes): 3 people, 10.71%

What are the existing conditions these people have? *

Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 2 people, 7.14%
Asthma: 1 person, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Velcade and have Gastrointestinal hypomotility?

- Check whether Gastrointestinal hypomotility is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Velcade:

Velcade (66,422 reports)

Browse all side effects of Velcade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal hypomotility:

Gastrointestinal hypomotility (205 drugs)

Browse all the conditions that are associated with Gastrointestinal hypomotility:

Gastrointestinal hypomotility (437 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bortezomib (the active ingredients of Velcade) and Velcade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.